In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Stevenson, Independent Director and Pharma industry veteran.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:
- Bringing an outsourcing model from UpjohnPharmacia into Pfizer and then driving manufacturing out of Pfizer into CDMOs without compromising on quality or IP
Behind the scenes of Pfizer's mammoth acquisitions of
Wyeth and
Hospira
The failure to spend too much time setting up a reliable, high-quality outsourcing network in China
The different perspectives of being 'the mayor of one huge site' to having a diversified, helicopter view across several
Switching from buy-side external outsourcing to running
Pfizer's CDMO division
Pfizer CentreOne
Don't be penny-wise and pound-foolish when balancing the onshoring manufacturing conundrum and how price controls in the US will impact all aspects of the industry
Peter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a Pfizer’s Global Manufacturing Leadership Team member, responsible for global procurement, global external supply, and a portfolio of Pfizer's internal manufacturing sites in North America, Europe, and Asia. Today, he is a Non-Executive Independent Board Member at Piramal Pharma.
Later, Mr. Stevenson served as General Manager of Pfizer’s contract manufacturing business and Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.
Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese, including a 3-year expatriate assignment in France. He has a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
